William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on SPRY stock, giving a Buy rating on September 6.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lachlan Hanbury Brown has given his Buy rating due to a combination of factors related to ARS Pharmaceuticals’ recent developments. The company announced that results from the neffy Experience program, which demonstrated real-world clinical effectiveness, were accepted for publication in a reputable journal. This publication provides substantial evidence of neffy’s performance in treating anaphylaxis symptoms in a large cohort of patients, aligning closely with existing data on traditional epinephrine treatments.
These findings are significant as they address previous concerns about neffy’s efficacy, which were primarily based on pharmacokinetic and pharmacodynamic data. The real-world data indicate that a high percentage of patients were successfully treated with a single dose, comparable to traditional methods. This strengthens the clinical profile of neffy and is expected to support its adoption in the market. Despite the timing of the publication, which may not immediately influence prescribing behaviors, it is anticipated to play a crucial role in the company’s future marketing strategies.
In another report released on September 6, Cantor Fitzgerald also maintained a Buy rating on the stock with a $25.00 price target.